Roivant Sciences Ltd Overview
Industry: Biotechnology
Sector: Healthcare
Read MoreReported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $1.4M (-34% YoY). Net loss was -$290.6M (from $273.9M). Cash was $3.9B.
Revenue
$1.4M
-34% YoY
Net loss
-$290.6M
from $273.9M
Cash
$3.9B
reported
What changed
- Revenue -34% YoY to $1.4M.
- Net loss was -$290.6M (from $273.9M).
Guidance / outlook
we expect topline readouts from our NIU, PH-ILD and CLE studies before year end.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
Aug 06, 2026
SEC filing
8-K
Aug 06, 2026
SEC filing
10-K
May 20, 2026
Earnings release
Earnings release
May 20, 2026
SEC filing
8-K
May 20, 2026
SEC filing
8-K
Apr 02, 2026
Earnings release
Earnings release
Feb 06, 2026
SEC filing
10-Q
Feb 06, 2026
SEC filing
8-K
Feb 06, 2026
SEC filing
10-Q
Nov 10, 2025
Earnings release
EXHIBIT 99.1
Nov 10, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Roivant Sciences Ltd. Q1 2026 Earnings Call Summary
Headline from Yahoo Finance: Roivant Sciences Ltd. Q1 2026 Earnings Call Summary.
Roivant Sciences Q1 Earnings Call Highlights
Headline from Yahoo Finance: Roivant Sciences Q1 Earnings Call Highlights.
Roivant Sciences earnings beat by $0.04, revenue fell short of estimates
Headline from Investing.com: Roivant Sciences earnings beat by $0.04, revenue fell short of estimates.
Roivant Sciences Ltd (ROIV) (Q1 2026) Earnings Call Highlights: Strategic Advances and Strong ...
Headline from Yahoo Finance: Roivant Sciences Ltd (ROIV) (Q1 2026) Earnings Call Highlights: Strategic Advances and Strong .
Roivant Sciences Ltd. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:ROIV) 2026-08-06
Headline from Seeking Alpha: Roivant Sciences Ltd. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:ROIV) 2026-08-06.
Roivant earnings in focus as mosliciguat trial data looms
Headline from Investing.com India: Roivant earnings in focus as mosliciguat trial data looms.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.